Aim 3 Sample Clauses

Aim 3. Examine Transition Assessment Literature & Identify Transition Factors From the literature search and review, 6 studies evaluating the success of transition and identifying challenges to transition were found to be relevant. These papers were used as the basis for extracting and categorizing common factors affecting a successful transition process. The criteria for including the factors were that 1) the factor was identified in at least one paper, 2) the factor was considered by the authors to be an important yet not adequately considered in the transition assessments run by Gavi or Global Fund, and 3) it is a factor not taken into consideration in the current Eligibility, Transition, and Co-financing Policies of Gavi or the Global Fund. These factors were then organized in Microsoft Excel to roughly represent the frequency and the time period in which these factors began to be analyzed, and whether their analysis recurred in subsequent papers. Table 5 shows a simple list of the identified factors from these 6 papers.
Sample 1
AutoNDA by SimpleDocs
Aim 3 i. We will continue working to identify meaningful discoveries (not only medical product candidates, but technologies developed in all of our scientific disciplines across our three UM campuses (e.g. engineering, medicine, physics, marine biology, etc.) and help research teams to develop them, and to advance those discoveries through all the stages required toward commercialization.
Sample 1
Aim 3 a. The RTS-Smartstore DNA storage robotic system, within the Hussman Institute Biorepository is now fully operational and implemented into the Nautilus LIMs system.
Sample 1
Aim 3. Both the Division (1.a above) and the Prevention Science and Methodology Group (PSMG) provide organizational support for this goal. The PSMG network, established 10 years ago and comprising more than 170 researchers and methodologists, conducts interdisciplinary methods presentations through weekly grand-rounds conference calls and facilitatesmethodological development and application in leading edge research nationally. Xx. Xxxxx heads this group, and Xx. Xxxxxxxxx has joined PSMG's steering committee so that it can address the Miami CTSI agenda for developing translational biostatistics research. This Component has also created a small grant program to stimulate cross-school collaborations in methodological development.
Sample 1
Aim 3. We plan to produce a paper on Scientific Equity that maps out design requirements for randomized trials of interventions and strategies for synthesizing findings from the literature related to health disparities. We, along with our collaborators, plan to submit an NIH application to develop the biostatistical and psychometric methodology for extending computerized adaptive testing to minority populations. This method would identify items that display differential item functioning as well as different underlying psychometric structures. We plan to submit this as an extension of measuring depressive, anxious, and bipolar symptoms in a Spanish speaking population as a model that can be generalized to other medical conditions and populations.
Sample 1
Aim 3. To develop degree-granting and formal early career mentored programs that will expand and diversify the research workforce, with a particular focus on addressing health care disparities and culturally appropriate research methods.
Sample 1
Aim 3. Our trainee, Dr. Xxxxx Kenya was selected as one of the four initial CTSI pilot trainees. Her project focuses on use home based Rapid HIV testing as a means to increase HIV screening in underserved African-American communities, one of the priority areas highlighted by the CTSI Community Advisory Board. Medical Student Xxxxxx Xxxxxx, building on a project showing high rates of dirty needles in Miami due to lack of needle exchange programs (another CAB identified community priority), has spearheaded a medical student led State-Wide campaign to write and introduce House and Senate bills in FL allowing for needle exchange programs in the state. This initiative has garnered 500 hours of service from the Florida Medical Association, the full support of our University’s lobbyists, support from over 10 State-wide organizations, Bills introduced in the State House and Senate and committee hearings.
Sample 1
AutoNDA by SimpleDocs

Related to Aim 3

  • Přetrvávající platnost Tento odstavec 1.3 “Zdravotní záznamy a Studijní data a údaje” zůstane závazný i v případě zániku platnosti či vypršení platnosti této Smlouvy.

  • Technology Research Analyst Job# 1810 General Characteristics Maintains a strong understanding of the enterprise’s IT systems and architectures. Assists in the analysis of the requirements for the enterprise and applying emerging technologies to support long-term business objectives. Responsible for researching, collecting, and disseminating information on emerging technologies and key learnings throughout the enterprise. Researches and recommends changes to foundation architecture. Supports research projects to identify and evaluate emerging technologies. Interfaces with users and staff to evaluate possible implementation of the new technology in the enterprise, consistent with the goal of improving existing systems and technologies and in meeting the needs of the business. Analyzes and researches process of deployment and assists in this process.

  • Přetrvající platnost This Section 3 “

  • Synchronization, Commissioning and Commercial Operation 4.1.1 The Power Producer shall give at least thirty (30) days written notice to the SLDC and GUVNL, of the date on which it intends to synchronize the Power Project to the Grid System.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • SMT XXXXXXXXX XXX, (PAN: XXXXX0000X), wife of Xxx Xxxxxx Xxx, by Nationality Indian, by faith Hindu, by occupation Housewife, residing at Village- Akrampur, PIN-743263, P.O. Akrampur, P.S. Habra, District North 24 Parganas, State West Bengal and (6) SRI XXXXXX XXX, (PAN-XXXXX0000X), son of Xxx Xxxxx Xxxxxx Dey, by Nationality Indian, by faith Hindu, by occupation Service, residing at Village- Akrampur, PIN – 743263, P.O. Akrampur, P.S. Habra, District North 24 Parganas, State West Bengal, hereinafter called and referred to as the VENDORS, all being represented by their Constituted Attorney, XXX XXXXX XXXXXX, (PAN: XXXXX0000X), son of Xxx Xxxxx Xxxxxx, by nationality Indian, by faith Hindu, by occupation Business, residing at BE-111, Sector-I, Salt Lake, Kolkata-700064, Post Office AE Market (Salt Lake City), Police Station Bidhannagar (North), District North 24 Parganas, and being one of the Directors of MAGNOLIA INFRASTRUCTURE DEVELOPMENT LIMITED, (CIN: U70200WB2010PLC152199), (PAN-XXXXX0000X), a Company incorporated under the provisions of the Companies Act, 1956 and having its registered office at 00, Xx. Xxxxxx Xxxxxxx Banerjee Road, Kolkata-700010, Post Office Beliaghata, Police Station: Beliaghata, District South 24 Parganas vide (1) Development Power of Attorney after registration of Development Agreement dated 12th September 2015 registered in the Office of the Additional District Sub-Registrar, Kadambagachi, North 24 Parganas and recorded in Book-I, Volume No. 1519-2015, at Pages 18496 to 18541, being No. 151901639 for the year 2015 and (2) Development Power of Attorney after registration of Development Agreement dated 19th November 2018 registered in the Office of the Additional District Sub-Registrar, Kadambagachi, North 24 Parganas and recorded in Book-I, Volume No. 1519-2015, at Pages 80220 to 80243, being No. 151903193 for the year 2018 (which expression shall unless excluded by or repugnant to the subject or context be deemed to mean and include their respective successors – interest and/or assigns) of the ONE PART. AND MAGNOLIA INFRASTRUCTURE DEVELOPMENT LIMITED, (CIN: U70200WB2010PLC152199), (PAN-XXXXX0000X), a Company incorporated under the provisions of the Companies Act, 1956 and having its registered office at 00, Xx. Xxxxxx Xxxxxxx Banerjee Road, Kolkata -700010, Post Office Beliaghata, Police Station: Beliaghata, District South 24 Parganas, being represented by its Director, XXX XXXXX XXXXXX, (PAN: XXXXX0000X), (AADHAAR NO: 000000000000), son of Xxx Xxxxx Xxxxxx, by nationality Indian, by faith Hindu, by occupation Business, residing at XX-000, Xxxxxx-X, Xxxx Xxxx, Xxxxxxx- 000000, Post Office AE Market (Salt Lake City), Police Station Bidhannagar (North), District North 24 Parganas, hereinafter called and referred to as the “DEVELOPER” (which expression shall unless repugnant to the context or meaning thereof shall include its successors-in-interest and/or permitted assigns of the SECOND PART. AND

  • Tests and Preclinical and Clinical Trials The preclinical studies and clinical trials conducted by or, to the Company’s knowledge, on behalf of the Company, that are described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, as applicable, and are intended to be submitted to FDA or other comparable government entities, were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all Authorizations and Applicable Laws, including, without limitation, the Federal Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder and for studies submitted to regulatory authorities for approval, current Good Clinical Practices and Good Laboratory Practices and any applicable rules and regulations of the jurisdiction in which such trials and studies are being conducted; the descriptions of the results of such studies and trials contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus are, to the Company’s knowledge, accurate and complete in all material respects and fairly present the data derived from such studies and trials; except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company is not aware of any studies or trials, the results of which the Company believes reasonably call into question the study or trial results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus when viewed in the context in which such results are described and the clinical stage of development; and, except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package or the Prospectus, the Company has not received any written notices or written correspondence from the FDA or any governmental entity requiring the termination or suspension of any preclinical studies or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials, copies of which communications have been made available to you.

  • Vlastnictví Zdravotnické zařízení si ponechá a bude uchovávat Zdravotní záznamy. Zdravotnické zařízení a Zkoušející převedou na Zadavatele veškerá svá práva, nároky a tituly, včetně práv duševního vlastnictví k Důvěrným informacím (ve smyslu níže uvedeném) a k jakýmkoli jiným Studijním datům a údajům.

  • Problem Solving Employees and supervisors are encouraged to attempt to resolve on an informal basis, at the earliest opportunity, a problem that could lead to a grievance. If the matter is not resolved by informal discussion, or a problem-solving meeting does not occur, it may be settled in accordance with the grievance procedure. Unless mutually agreed between the Employer and the Union problem-solving discussions shall not extend the deadlines for filing a grievance. The Union Xxxxxxx or in their absence, the Local Union President, or Area Xxxxxxx, or Chief Xxxxxxx, either with the employee or alone, shall present to the appropriate supervisor a written request for a meeting. If the supervisor agrees to a problem- solving meeting, this meeting shall be held within fourteen (14) calendar days of receipt of the request. The supervisor, employee, Union Xxxxxxx, and up to one (1) other management person shall attempt to resolve the problem through direct and forthright communication. If another member of management is present that person will not be hearing the grievance at Step Two, should it progress to that Step. The employee, the Union Xxxxxxx or in their absence, the Local Union President, or Area Xxxxxxx, or Chief Xxxxxxx, may participate in problem-solving activities on paid time, in accordance with Article 31, Union Rights, Section 1H.

  • Manufacturing and Marketing Rights The Company has not granted rights to manufacture, produce, assemble, license, market, or sell its products to any other person and is not bound by any agreement that affects the Company's exclusive right to develop, manufacture, assemble, distribute, market, or sell its products.

Time is Money Join Law Insider Premium to draft better contracts faster.